243 related articles for article (PubMed ID: 32996801)
1. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
3. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Iizuka Y; Takase-Minegishi K; Hirahara L; Kirino Y; Soejima Y; Namkoong HO; Horita N; Yoshimi R; Takeuchi M; Takeno M; Mizuki N; Nakajima H
Mod Rheumatol; 2022 Oct; 32(6):1153-1162. PubMed ID: 34752620
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
[TBL] [Abstract][Full Text] [Related]
7. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
10. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G; Mahr A; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35798511
[TBL] [Abstract][Full Text] [Related]
11. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
12. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
[TBL] [Abstract][Full Text] [Related]
13. Interventions for the management of oral ulcers in Behçet's disease.
Taylor J; Glenny AM; Walsh T; Brocklehurst P; Riley P; Gorodkin R; Pemberton MN
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD011018. PubMed ID: 25254615
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.
Mirouse A; Barete S; Desbois AC; Comarmond C; Sène D; Domont F; Bodaghi B; Ferfar Y; Cacoub P; Saadoun D;
Arthritis Rheumatol; 2019 Oct; 71(10):1727-1732. PubMed ID: 31008548
[TBL] [Abstract][Full Text] [Related]
15. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
16. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
[TBL] [Abstract][Full Text] [Related]
17. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Atienza-Mateo B; Martín-Varillas JL; Graña J; Espinosa G; Moriano C; Pérez-Sandoval T; García-Armario MD; Castellví I; Román-Ivorra JA; Olivé A; Ybáñez A; Martinez-Ferrer A; Narváez J; Romero-Yuste S; Ojeda S; Ros I; Loricera J; Calvo-Río V; Castañeda S; Gonzalez-Gay MA; Blanco R;
Clin Exp Rheumatol; 2020; 38 Suppl 127(5):69-75. PubMed ID: 33331268
[TBL] [Abstract][Full Text] [Related]
18. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
19. [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
Fourmond S; Gutierrez B; Gourin MP; Delaumenie S; Ly KH
Rev Med Interne; 2022 May; 43(5):312-315. PubMed ID: 35219509
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
